(NASDAQ: PVLA) Palvella Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Palvella Therapeutics's revenue in 2025 is -$53,000.On average, 2 Wall Street analysts forecast PVLA's revenue for 2027 to be $55,554,717, with the lowest PVLA revenue forecast at $51,519,399, and the highest PVLA revenue forecast at $59,590,034. On average, 2 Wall Street analysts forecast PVLA's revenue for 2028 to be $453,226,987, with the lowest PVLA revenue forecast at $173,684,497, and the highest PVLA revenue forecast at $732,769,476.
In 2029, PVLA is forecast to generate $1,338,232,970 in revenue, with the lowest revenue forecast at $888,875,466 and the highest revenue forecast at $1,787,590,474.